Attendee search 

Phytecs is a biotechnology company developing therapies that target the body’s endocannabinoid system (ECS). Phytecs’ lead semi-synthetic drug candidate is a propriety, fluorinated CBD (F-CBD) compound. Preclinical research demonstrates that F-CBD mimics traditional CBD pharmacology with significantly lower dose requirements. Phytecs’ development pipeline also includes proprietary raw materials and formulations that leverage the synergistic effects of natural compound to produce medicines that are more effective, and safer, than those commonly found in botanicals or isolated natural compounds. Phytecs’ robust patent portfolio spans three continents and is the direct result of its unwavering commitment to research and innovation.

Miller Thomson is one of Canada’s leading business law firms with the broadest geographic reach of any in the country. Our 550 lawyers based in 12 offices enable our firm to consistently deliver the highest quality legal services required by domestic and international clients doing business in Canada.  Quick to establish a national Cannabis Industry Group, Miller Thomson is now frequently advising clients on  legal issues that are pertinent in all stages of a cannabis business, from initial start-up to licensed producer.  Our expertise and experience cover matters relevant to corporate and commercial, mergers and acquisitions, capital markets and securities, regulatory compliance, advertising, intellectual property, employment and tax. We also frequently provide strategic advice for companies in the cannabis industry relating to debt and equity financings, initial public offerings, reverse take-overs and direct listings on the Toronto Stock Exchange, TSX Venture Exchange, or the Canadian Securities Exchange. 

IMC – International Medical Cannabis, one of the 8 government licensed cannabis growers in Israel. Our operation is on an Industrial scale, in compliance with strict Israeli cannabis regulations, assuring security, quality and GAP certification.

IMC is continuing to maintain a leadership position in the Israeli medical cannabis sector and has made great strides towards entering the EU market.

Globally, the expertise and tremendous intellectual property developed within has positioned IMC as world leaders and experts in medical cannabis. This is a strategic advantage that sets us apart from licensed cannabis producers around the globe.